Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Adagene ( (ADAG) ) has provided an update.
On January 23, 2026, Adagene reported unaudited cash and cash equivalents of $74.5 million as of December 31, 2025, which it expects to fund operations into late 2027, and detailed a series of 2025 milestones centered on its lead CTLA-4 antibody muzastotug and its SAFEbody technology platform. Over the past year, the company presented Phase 1b/2 data in microsatellite stable colorectal cancer showing encouraging responses at high doses, secured FDA Fast Track designation and end-of-Phase 1 alignment for muzastotug, initiated a randomized Phase 2 dose-optimization study, and expanded strategic partnerships with Sanofi, Third Arc Bio, Exelixis and ConjugateBio, underscoring growing external validation of its platform and adding non-dilutive support for clinical development. For 2026, Adagene plans multiple data readouts from ongoing muzastotug combination trials in colorectal and liver cancer and aims to complete Phase 2 enrollment and secure additional collaborations, steps that could sharpen its late-stage development path, strengthen its competitive positioning in next-generation immuno-oncology, and provide key catalysts for investors over the next two years.
The most recent analyst rating on (ADAG) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Adagene stock, see the ADAG Stock Forecast page.
Spark’s Take on ADAG Stock
According to Spark, TipRanks’ AI Analyst, ADAG is a Neutral.
The score is held down primarily by poor financial performance (sharp revenue decline, heavy losses, and negative/worsening cash flows). Technicals are a relative positive with price above key moving averages and a positive MACD, but valuation remains pressured by ongoing losses and no dividend support.
To see Spark’s full report on ADAG stock, click here.
More about Adagene
Adagene Inc. is a clinical-stage biotechnology company focused on developing novel antibody-based cancer immunotherapies. Leveraging computational biology, artificial intelligence and its proprietary Dynamic Precision Library platform, including NEObody, SAFEbody and POWERbody technologies, the company engineers masked antibodies designed to improve safety and tolerability by activating selectively in the tumor microenvironment. Its lead program, muzastotug (ADG126), is a masked anti-CTLA-4 SAFEbody with FDA Fast Track designation, being developed primarily in combination with anti-PD-1 therapy for microsatellite stable metastatic colorectal cancer, alongside multiple collaborations with global pharma partners that apply its SAFEbody platform across advanced antibody modalities.
Average Trading Volume: 129,724
Technical Sentiment Signal: Strong Sell
Current Market Cap: $88.14M
Learn more about ADAG stock on TipRanks’ Stock Analysis page.